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BACKGROUND. Recently, we established paclitaxel-resistant prostate cancer cell lines
(PC-3-TxR and DU145-TxR). To determine the mechanisms of paclitaxel resistance in PC-3-
TxR cells, we compared the gene expression profiles between PC-3 and PC-3-TxR cells.
Our results indicated that expression of the C-terminal tensin like protein (CTEN, tensin 4)
gene was down-regulated by 10-fold in PC-3-TxR cells. We investigated the possibility that
CTEN overexpression restores paclitaxel sensitivity.
METHODS. We investigated how knockdown and overexpression of CTEN in androgen-
independent cell lines affect paclitaxel sensitivity by colony formation assay and growth
inhibition assay. To determine the mechanisms by which CTEN affects paclitaxel sensitivity, we
investigated the relationships between CTEN and F-actin or epidermal growth factor receptor
(EGFR) in PC-3 cells. We also examined the association between expression of CTEN and grade
of prostate cancer by immunohistochemistry using tissue microarray analysis.
RESULTS. Down-regulation of CTEN, which is located in the cytoskeleton, played an
important role in paclitaxel resistance in PC-3-TxR cells. Knockdown of CTEN expression in
PC-3 cells induced paclitaxel resistance. Overexpression of CTEN in PC-3-TxR and DU145-TxR
cells restored paclitaxel sensitivity. CTEN expression was inversely correlated with F-actin and
EGFR expression. Then knockdown of actin and EGFR in PC-3-TxR cells recovered paclitaxel
sensitivity, indicating that CTEN down-regulation mediates paclitaxel resistance through
elevation of EGFR and actin expression. Moreover, CTEN expression was inversely correlated
with Gleason score.
CONCLUSIONS. These results strongly suggested that CTEN plays an important role in
paclitaxel sensitivity and that CTEN expression level may be a prognostic predictive factor for
PCa patients. Prostate 70: 48–60, 2010. # 2009 Wiley-Liss, Inc.
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INTRODUCTION
Prostate cancer (PCa) is a major public health
problem as it is the most commonly diagnosed cancer
and the leading cause of cancer-related death in
American men [1]. Hormonal therapy (i.e., androgen
deprivation) initially induces antitumor response in
more than 90% of patients. However, it eventually fails
and the PCa progresses to an androgen-insensitive
stage that is essentially incurable [2]. Chemotherapy
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plays an increasingly important role in the manage-
ment of androgen-insensitive metastatic PCa. Recently,
taxanes (paclitaxel or docetaxel—DTX) in combination
with other agents, such as estramustine phosphate
(EMP), or dexamethasone, for treating hormone-
refractory PCa and have been shown to induce good
antitumor responses [3–6]. Paclitaxel acts as an anti-
tumor drug by disrupting the cell cycle through
stabilizing microtubule polymers [7]. The microtubule
cytoskeleton is a highly regulated system. At
different times in the cell cycle, microtubules can be
very stable or highly dynamic. Stability and dynamics
are regulated by interaction with a large number
of proteins that themselves may change at specific
points in the cell cycle [8]. Exogenous ligands such as
paclitaxel can disrupt the normal processes by either
increasing or decreasing microtubule stability and
inhibiting their dynamic behavior [8].
Although hormone-resistant PCa initially responds
to paclitaxel-based chemotherapy, PCa eventually
becomes resistant to paclitaxel. One of main mecha-
nisms of drug resistance is overexpression of the
multiple drug resistance gene (MDR-1)-encoded
P-glycoprotein, a drug transporter belonging to the
ATP-binding cassette [9]. Taxane resistance has also
been observed in several cancers. For example, in breast
cancer, down-regulation of the gene encoding ribo-
pholin II (RPN2) mediates DTX resistance by reducing
glycosylation of P-glycoprotein [10]. In ovarian cancers,
overexpression of FOXO1 involving oxidative stress
also contributes to drug resistance [11]. In pancreatic
cancer, inhibition of BCL-2 alters diverse pathways that
control cell survival and thus overcomes paclitaxel
resistance [12].
We have previously established paclitaxel-resistant
DU145-TxR and PC-3-TxR cells from DU145 and PC-3
cell lines. In DU145 cells, paclitaxel resistance was due
to overexpression of P-glycoprotein in DU145-TxR [13].
However, in PC-3-TxR cells, knockdown of MDR-1
gene expression did not reverse paclitaxel resistance,
suggesting that other mechanisms are involved in
paclitaxel resistance of PC-3-TxR cells [13]. Therefore,
we performed cDNA microarray using mRNA from
the parent cell lines PC-3 and PC-3-TxR and compared
differentially expressed genes. Approximately 40,000
genes were screened by cDNA microarray analysis.
A total of 201 (1.34%) of the screened genes were up-
regulated by more than twofold, and 218 (1.45%) of the
genes were down-regulated by more than twofold
in PC-3-TxR cells compared with PC-3 cells [13].
We hypothesized that some of these genes mediated
paclitaxel resistance in PC-3-TxR cells. We initially
focused on C-terminal tensin-like protein (CTEN), gene
expression of which was down-regulated by 10-fold
in PC-3-TxR cells [13].
CTEN is a recently isolated focal adhesion molecule.
Human CTEN cDNA encodes a 715-amino acid
sequence containing the Src homology 2 (SH2) and
phosphotyrosine-binding (PTB) domains, which are
similar to the COOH termini of tensin molecules that
belong to the four-member tensin family (tensin 1,
tensin 2, tensin 3, and CTEN) [14]. The proteins
encoded by these genes are localized to the cytoplasmic
side of focal adhesions [14]. In the present study,
we examined whether decreased CTEN expression
contributes to paclitaxel resistance in PCa cells.
MATERIALSANDMETHODS
Antibodies and Reagents
The following primary antibodies were used: poly-
clonal anti-CTEN serum was raised by immunization
of peptide 653–655 amino acid into a rabbit (Takara Bio,
Otsu, Japan), rabbit polyclonal anti-GAPDH, anti-actin,
and anti-EGFR were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Goat anti-rabbit IgG
(HþL)-HRP Conjugate was purchased from Bio-Rad
(Hercules, CA). Paclitaxel (PTX) was purchased from
Bristol Pharmaceuticals Y.K. (Tokyo, Japan). EMP,
DTX, doxorubicin (DOX), VP-16 (etoposide), vinblas-
tine (VLB), and cisplatin (CDDP) were purchased from
Sigma (St. Louis, MO). Epidermal growth factor
receptor (EGFR) inhibitor PD153035 was purchased
from Calbiochem (La Jolla, CA).
Cell Lines andCell Culture
Paclitaxel-resistant PC-3-TxR and DU145-TxR cells
were generated and maintained as described previ-
ously [13]. The PC-3-TxR cells were cultured in 10 nM
paclitaxel to maintain their drug-resistant phenotypes.
Before each experiment, these cells were grown for
a minimum of 1 day in normal medium. The PC-3 and
PC-3-TxR cells were maintained in RPMI1640 (Sigma)
supplemented with 5% fetal bovine serum (FBS) and
1% penicillin/streptomycin (Invitrogen, Carlsbad,
CA). DU145 and DU145-TxR cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM; Sigma)
supplemented with 5% FBS.
ProliferationAssay
Cell growth or growth inhibition assay was per-
formed by plating 2 105 cells on 6-well plates. After
cultured for 24 hr, cells were treated with the indicated
concentrations of anticancer agents (PTX, EMP, DTX,
DOX, VP-16, VLB, and CDDP) or EGFR inhibitor
PD153035 and cultured for an additional 48 hr. At the
end of the culture period, the cells were trypsinized and
counted using a hemocytometer. The relative cell
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numbers compared with untreated controls were
plotted as cell viability.
PlasmidTransfection
To generate a CTEN expression plasmid, the open
reading frame of the CTEN gene was generated by
RT-PCR using cDNA synthesized from PC-3 cells using
the forward primer 50-ATCTCTGGGATGTCAGTGA-
GGCTGGTTG-30 and the reverse primer 50-GATGA-
TGGTGACTGCTGAAGGCCATAGC-30. After double
digestion with XbaI and BamHI, the PCR product was
cloned into the respective restriction sites of the pBK-
CMV-neo vector (Stratagene, La Jolla, CA). The insert
was confirmed by sequencing from both directions,
and the plasmid was named pBK-CMV-CTEN. PC-3-
TxR and DU145-TxR cells were transfected with pBK-
CMV-CTEN or pBK-CMV-neo using Lipofectamine
reagent (Invitrogen, San Diego, CA) Eight h after
transfection, the cells were cultured in medium con-
taining 800 mg/ml G418 (Sigma) and selected as stable
CTEN-overexpressing cells.
Colony FormationAssay
Cells were seeded at a density of 1.0 103 on 6-well
plates, and allowed to adhere for 24 hr. The cells
were then treated with the indicated concentrations
of paclitaxel, and medium was replaced with fresh
medium after 24 hr and every 3 days thereafter. The
cells were allowed to grow for 10 days, then fixed using
methanol and stained with 1% crystal violet, and the
numbers of colonies containing>50 cells were counted.
Treatment with each dose was performed in tripli-
cate and the experiments were performed at least
three times. The relative numbers of colonies compared
with untreated controls were plotted as cell viability.
RNAInterferenceAnalysis
The specific Stealth CTEN and actin small interfer-
ing RNA (siRNA) were synthesized by Invitrogen.
CTEN and actin target siRNA sequence were 50-AA-
UGUAGGAGUCAAGGUCCUCUGGG-30 and 50-AU-
CUCUUUCUGCAUGCGGUCAGCGA-30, respectively.
Validated Stealth EGFR siRNA and non-targeting
siRNA (NT siRNA) were purchased from Invitrogen.
For CTEN knockdown, PC-3, PC-3-TxR, DU145, and
DU145-TxR cells were plated into 6-well plates at
3 105 cells/well, respectively. Cells were then trans-
fected with 20 nM of CTEN siRNA or NT siRNA using
X-treme GENE siRNA Transfection Reagent (Roche,
Indianapolis, IN) for 24 hr. Total proteins were
extracted 48 hr after transfection. Twenty-four hours
after transfection with 20 nM NT siRNA or CTEN
siRNA, cells were treated with the indicated concen-
trations of paclitaxel for 48 hr, cultured for 48 hr, and
counted using a hemocytometer. For actin and EGFR
knockdown, 24 hr after transfection with 20 nM of NT
siRNA, actin, or EGFR siRNA, cells were treated with
the indicated concentrations of paclitaxel for 48 hr and
counted.
Western BlotAnalysis
Twenty-four hours after plating, total protein was
extracted from PC-3, PC-3-TxR, DU145, and DU145-
TxR cells as described previously [15]. The subcellular
protein (cytosol membrane nucleus and cytoskeleton
protein) was extracted using a ProteoExtract Subcel-
lular Proteome Extraction kit (Calbiochem). Aliquots of
30 mg of total protein of subcellular proteins were
separated by 10% Ready Gel J (Bio-Rad), and electro-
blotted onto PVDF membranes (Bio-Rad), blocked with
5% skimmed milk, and reacted with anti-CTEN or
rabbit polyclonal anti-GAPDH (Santa Cruz). The first
antibody was recognized by goat anti-rabbit secondary
antibody (Bio-Rad) and visualized using enhanced
chemiluminescence (Amersham Pharmacia Biotech,
Piscataway, NJ).
Immunofluorescence
Staining for tubulin, filamentous actin (F-actin) and
CTEN protein was performed by overnight incubation
using commercial kits in accordance with the manu-
facturer’s instructions (Oregon Green1 488 conjugate
kit, Phallotoxins and ZenonTM Tricolor Mouse and
Rabbit IgG Labeling Kit; Molecular Probes, Eugene,
OR), Briefly, cells were fixed with 4% paraformalde-
hyde for 10 min, washed three times with PBS, and
blocked with 5% bovine serum albumin (Sigma) for
15 min. Slides were then washed three times with PBT
(0.1% Triton X-100 in PBS), incubated with anti-CTEN
antibody for 1 hr at 378C, and cells were washed
three times with PBT. The cells were then incubated
with 5 mg/ml Alexa Flour 555 goat anti-rabbit IgG to
detect anti-CTEN antibody in 1% BSA/PBT for 1 hr at
378C. The cells were also washed three times with PBT,
and then incubated with Oregon Green1 488 conjugate
kit to detect tubulin and Alexa Flour 488 phalloidin
diluted 1:200 from stock solution for 1 hr at 378C to
detect F-actin. The cells were washed three times with
PBS, and mounted with Vectashield mounting medium
with 40, 6-diamidino-2-phenylindole (DAPI) to detect
nuclei. The slides were imaged using a confocal
microscope.
Immunohistochemistryof TissueMicroarray
PR951 and PR952 tissue microarrays (TMAs) com-
prised of 176 cores from 88 cases containing normal
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tissue, matched for Gleason score at surgery were
purchased from Biomax (Rockville, MD). TMA sections
were pretreated in 0.01 M sodium citrate buffer for
10 min in a microwave oven after overnight incubation
at 378C. Endogenous peroxidase was blocked with
0.3% hydrogen peroxide, followed by incubation with
PBS containing 10% normal goat serum. Specimens
were incubated with anti-CTEN antibody at a dilution
of 1:150. The antibody-antigen complex was visualized
using the DakoCytomation LSABþ system-HRP
(Dako, Carpinteria, CA). All sections were counter-
stained with hematoxylin.
Statistical Analysis
The statistical significance of differences in prolifer-
ation was determined by two-way ANOVA with post
hoc test. Dunnett’s test was also performed to deter-
mine the significance of intensity differences on West-
ern blotting analysis. *P< 0.05 and **P< 0.01 were
considered statistically significant. Kruskal–Wallis test
was used to determine the statistical significance of
differences in immunohistochemical staining. The data
represent the means SD of three replicates.
RESULTS
Down-Regulation of CTENExpression in
Paclitaxel-Resistant PC-3 Cells
In a previous study, we established paclitaxel-
resistant PC-3 cells (PC-3-TxR) from androgen-
independent PCa cells (PC-3). First, we investigated
the expression level of a-tubulin and b-tubulin that
form microtubules. There were no differences in their
expression between PC-3 and PC-3-TxR cells (Fig. 1A).
We also examined the distribution pattern of micro-
tubules in these cells, but there were also no differences
in distribution of microtubules in PC-3 and PC-3-TxR
cells (Fig. 1B). Next, we reconfirmed paclitaxel resist-
ance in PC-3-TxR cells using colony formation assay.
PC-3-TxR cells were more resistant to paclitaxel than
the parental PC-3 cells (LD50: PC-3-TxR and PC-3, 30.2
and 2.0 nM, respectively) (Fig. 2A). To investigate
which genes are responsible for paclitaxel resistance,
we focused on those that were down-regulated in
paclitaxel-resistant cells. Thus, we investigated the
CTEN gene, which was down-regulated by 10-fold in
PC-3-TxR cells compared with PC-3 cells [13]. Western
blot analysis showed that CTEN was strongly
expressed in PC-3 cells but not in PC-3-TxR cells
(Fig. 2A). To investigate whether down-regulation of
CTEN expression occurred only during the process
of establishment of PC-3-TxR cells, in which the cells
were grown for a long period in paclitaxel, or whether
paclitaxel treatment rapidly and directly affects CTEN
expression, we treated PC-3 cells with paclitaxel and
examined CTEN expression. Treatment with paclitaxel
caused down-regulation of CTEN expression in PC-3
cells in a dose-dependent manner at 48 hr (Fig. 2B),
indicating that paclitaxel can rapidly down-regulate
CTEN expression. Down-regulated CTEN expression
in PC-3-TxR cells was irreversible even if we removed
paclitaxel from the culture medium for maintenance of
PC-3-TxR cells for at least 3 months (data not shown).
Involvementof CTENin Paclitaxel Sensitivity
We next investigated whether down-regulation of
CTEN contributes to the development of paclitaxel
resistance. Then we determined the effect of re-
expression of CTEN on paclitaxel resistance in PC-3-
TxR cells. We compared the sensitivity to paclitaxel
between PC-3-TxR cells transfected with a CTEN
expression vector (PC-3-TxR/CTEN) and those trans-
fected with empty pBK-CMV-neo vector (PC-3-TxR/
Neo). CTEN protein was detected at much higher levels
in PC-3-TxR/CTEN compared to PC-3-TxR/Neo cells
(Fig. 2C). CTEN overexpression did not affect the
proliferation of PC-3-TxR cells (Fig. 2C). To investigate
whether CTEN overexpression affects paclitaxel resist-
ance, we compared paclitaxel sensitivity between PC-3-
TxR/Neo and PC3-TxR/CTEN by colony formation
assay. The survival curve for paclitaxel was shifted to
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Fig. 1. Cellular microtubule structures of PC-3 and PC-3-TxR
cells.A:Westernblottinganalysis of a-tubulinandb-tubulinprotein
expression.B:Tubulin polymerization of PC-3 and PC-3-TxR cells.
Tubulins were stained with an Oregon Green1 488 conjugate kit
(green) and DAPI (blue). PC-3-TxR cells exhibited similar tubulin
polymerization(green) to theparentalPC-3cell line.
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the left by CTEN overexpression (LD50 of PC-3-TxR/
Neo and PC-3-TxR/CTEN: 15.2 and 4.5 nM, respec-
tively) (Fig. 2D), indicating that CTEN overexpression
restored sensitivity to paclitaxel although the degree of
restoration was not to the level of sensitivity observed
in parental PC-3 cells (Fig. 2A).
To determine whether a decrease in CTEN expres-
sion level confers resistance to paclitaxel, we trans-
fected PC-3 cells with CTEN siRNA or non-target (NT)
siRNA. Transfection with CTEN siRNA repressed the
expression of CTEN protein in PC-3 cells compared
with NT siRNA (Fig. 2E). PC-3 cells transfected with
CTEN siRNA showed greater resistance to paclitaxel
than PC-3 cells transfected with NT siRNA (LD50 of PC-
3/NT siRNA and PC-3/CTEN siRNA: 1.7 and 26.1 nM,
respectively) (Fig. 2E). These data indicated that
reduced CTEN expression can induce paclitaxel resist-
ance in PC-3 cells.
CTENOverexpression Recovers Paclitaxel
Sensitivity inOther Prostate Cancer Cells
We investigated whether CTEN overexpression
affects paclitaxel sensitivity of other paclitaxel-resistant
PCa cells as well as PC-3-TxR cells. Previously, we
established paclitaxel-resistant DU145 (DU145-TxR)
The Prostate
Fig. 2. Down-regulationofCTENexpressionisrelatedtopaclitaxelresistanceinPC-3cells.A:CTENexpressionandpaclitaxelsensitivityin
PC-3 and PC-3-TxR cells.Total proteins extracted fromuntreated PC-3 and PC-3-TxR cells were subjected toWestern blotting analysis of
CTENandGAPDH.Anti-CTENantibody and anti-GAPDHantibody wereused fordetection of 76kDaCTENand 37kDaGAPDHprotein,
respectively.Colony formation assaywasperformedasdescribedin theMaterials andMethods Section.B:RegulationofCTENexpressionby
paclitaxel.Westernblottinganalysis ofCTENwasperformedafter treatmentofPC-3cellswithpaclitaxel for48hr.Therelativeintensitycom-
paredwithuntreatedPC-3cellswascolumned.C:ProliferationofPC-3-TxR/NeoandPC-3-TxR/CTENcells.ThenumbersofPC-3-TxR/Neo
andPC-3-TxR/CTENcellswerecounted24,48,72,and96hrafterinoculationof2103cells.NS:no significantdifference.D: SensitivityofPC-
3-TxR/Neo andPC-3-TxR/CTENcells.Totalproteins extracted fromPC-3-TxR/Neo andPC-3-TxR/CTENcellswere subjected toWestern
blottinganalysisofCTENandGAPDH.Colony formationassayofPC-3-TxR/NeoandPC-3-TxR/CTENcellsafter treatmentwithpaclitaxelfor
24hr (A).E: knockdownofCTENexpressioninPC-3 cellsbyCTENsiRNAtransfection.Twenty-fourhours after transfectionwithNTsiRNA
or CTEN siRNA, total proteins from PC-3 cells were extracted and subjected toWestern blotting analysis of CTEN and GAPDH.Growth
inhibitionbypaclitaxelwas examinedafter transfectionwithNTsiRNA(PC-3/NTsiRNA)orCTENsiRNA(PC-3/CTENsiRNA) asdescribed
in theMaterials andMethodsSection.
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cells in addition to PC-3-TxR cells [13]. We first
reconfirmed that DU145-TxR cells were resistant to
paclitaxel compared to DU145 cells (Fig. 3A). We
had previously shown that increased expression of
P-glycoprotein contributes to paclitaxel resistance of
DU145-TxR cells [13]. Both DU145 and DU145-TxR
cells expressed similarly low levels of CTEN (Fig. 3A).
Therefore, we examined whether increased expression
of CTEN could reverse paclitaxel resistance of DU145-
TxR cells. These cells were stably transfected with
pBK-CMV-CTEN (DU145-TxR/CTEN cell) or pBK-
CMV-neo (DU145-TxR/Neo) (Fig. 3B). Overexpression
of CTEN did not affect cell proliferation of DU145-TxR
cells (Fig. 3B). Then, CTEN overexpression did not
reduce P-glycoprotein levels in DU145-TxR/CTEN
(Fig. 3C). However, CTEN overexpression partially
restored paclitaxel sensitivity (Fig. 3D, compare with
DU145 in Fig. 3A), suggesting that mechanisms other
than P-glycoprotein were involved in restoration of
paclitaxel sensitivity by CTEN.
CTENOverexpression Partly Recovers the
Sensitivity toOtherAntitumorDrugs
We also compared the cross-resistance to other
anticancer drugs, that is, DTX (docetaxel), VBL, VP-16
(etoposide), CDDP, DOX, and EMP, between PC-3-
TxR/Neo and PC-3-TxR/CTEN cells. CTEN over-
expression restored the sensitivity to DTX, which
belongs to the taxane family similar to paclitaxel
(Fig. 4). CTEN overexpression also partially restored
the sensitivity for CDDP, VP-16, VBL, DOX, and EMP,
suggesting that CTEN affects the sensitivity to different
anticancer drugs through a common pathway although
the main mechanisms of drug resistance are different
among these drugs (Fig. 4).
Mechanismsof Paclitaxel Resistance
byDown-Regulation of CTEN
To investigate the mechanisms by which decreased
CTEN expression promotes paclitaxel resistance in PCa
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Fig. 3. Overexpression ofCTENincreases sensitivity to paclitaxel inDU145-TxR cells.A:Total proteins fromDU145 andDU145-TxR cells
were subjected toWesternblotting analysis forCTENandGAPDH.Colony formation assayofDU145 andDU145-TxR cellswereperformed
as described in the Materials and Methods Section.B:Total proteins from DU145-TxR/Neo and DU145-TxR/CTEN cells were subjected to
Westernblotting analysis ofCTENandGAPDH.DU145-TxR/Neo andDU145-TxR/CTENcellproliferationwere comparedafter inoculation
of 2104 cells. NS: no significant difference.C: Comparison of P-glycoprotein expression among DU145, DU145-TxR, DU145-TxR/Neo,
andDU145-TxR/CTEN.D:Colony formationassaysofDU145-TxR/NeoandDU145-TxR/CTENcellswereperformedasdescribedinFigure1.
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cells, we first examined the differences in expression
level of apoptosis-related proteins because paclitaxel
initiates the apoptotic process by binding to b-tubulin
and promoting its polymerization [16]. We observed
no differences in expression of a-tubulin, b-tubulin,
caspase 3, 7, 8, 9, 10, bcl-2, bcl-xL, or bax proteins among
PC-3, PC-3-TxR, PC-3-TxR/Neo, and PC-3-TxR/CTEN
cells by Western blotting analysis (data not shown).
These results suggested that alterations of the apoptotic
response do not account for the development of
paclitaxel sensitivity.
We next examined the localization of CTEN protein
in PC-3 cells. The results of Western blotting analysis
of various subcellular fractions indicated that CTEN
protein was localized mainly at the cytoskeleton in
PC-3 cells (Fig. 5A). Immunofluorescence analysis
showed that CTEN expression was down-regulated
by treatment with paclitaxel as shown in Figure 1C
(Fig. 5B). As CTEN was localized at the cytoskeleton
similar to other tensins, we investigated the effects of
paclitaxel on the expression of F-actin, which is also
localized at the cytoskeleton. This analysis indicated
that F-actin was up-regulated by paclitaxel in PC-3 cells
(Fig. 5B). To determine whether the effects of paclitaxel
on expression of F-actin in PC-3 cells are due to the
changes in CTEN expression induced by paclitaxel, we
compared CTEN expression with F-actin expression in
PC-3, PC-3-TxR, PC-3-TxR/Neo, and PC-3-TxR/CTEN
cells. Immunofluorescence analyses of CTEN and
F-actin revealed an inverse correlation between CTEN
The Prostate





Fig. 5. LocalizationofCTENproteinandinvolvementof actininpaclitaxelresistance.A:Thesubcellularproteinfractions(cytoplasm,mem-
brane,nucleus,andcytoskeletonprotein)wereextractedasdescribedintheMaterialsandMethodsSectionandsubjectedtoWesternblotting
analysis forCTEN.B: Immunofluorescenceanalysis ofCTENandF-actinafter treatmentwithpaclitaxel.AfterPC-3cellswere treatedwithor
withoutpaclitaxel (30nM) for 24hr, immunofluorescence analyseswereperformedusingrabbit anti-CTENantibody (red),F-actin (green) as
describedin theMaterials andMethodsSection,andtheblue signalrepresentsnuclearDNAstaining (400magnification).C: Immunofluores-
cence analysis of CTENand F-actin in PC-3, PC-3-TxR,PC-3-TxR/Neo, and PC-3-TxR/CTEN cells and PC-3 transfectedwithNTsiRNAor
CTENsiRNA.Immunofluorescenceanalysiswasperformedasdescribedin(B).D:Effectsofactinexpressiononpaclitaxelsensitivity.PC-3-TxR
cells transfected with NTsiRNA (20nM) or actin siRNA (5,10, or 20nM) for 24hr were subjected toWestern blotting analysis of actin and
GAPDH. Anti-actin antibody and anti-GAPDHantibody were employed for detection of 43kDa actin and 37kDaGAPDHprotein, respec-
tively.PC-3-TxR cells transfectedwith 20nMNTor actin siRNA for 24hrwere treatedwithpaclitaxel for 24hr.Then, the cellswere cultured
for48hr innormalmedium.
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and F-actin expression among these cell lines (Fig. 5C).
Moreover, knockdown of CTEN in PC-3 cells by
CTEN siRNA transfection induced F-actin expression
(Fig. 5C). To confirm whether down-regulation of actin
expression changed paclitaxel sensitivity, we knocked
down actin expression by transfection of actin siRNA
into PC-3-TxR cells and examined paclitaxel sensitivity.
Knockdown of actin partially restored paclitaxel
sensitivity (Fig. 5D). These results suggest that one of
the mechanisms through which paclitaxel resistance
is induced by down-regulation of CTEN expression is
associated with elevation of actin, which is localized to
the same region as CTEN.
AnotherMechanismof Paclitaxel Resistanceby
Down-Regulation of CTEN
Recently, several groups demonstrated that EGFR is
involved in paclitaxel resistance. Paclitaxel-resistant
cells expressed higher levels of EGFR, and EGFR
tyrosine kinase inhibitor was more effective in resistant
cells than in paclitaxel-sensitive cells [17–20]. There-
fore, we postulated that CTEN may affect EGFR
expression and modulate paclitaxel sensitivity. To
explore this possibility, we compared the expression
of EGFR between PC-3 and PC-3-TxR cells. EGFR
expression was elevated to a greater extent in PC-3-TxR
cells than in the parental PC-3 cell line (Fig. 6A). To
confirm the effect of CTEN on EGFR expression, we
compared EGFR expression between PC-3-TxR/Neo
and PC-3-TxR/CTEN cells. Overexpression of CTEN in
PC-3-TxR down-regulated EGFR expression (Fig. 6A).
In addition, we knocked down CTEN in PC-3, which
resulted in up-regulation of EGFR expression (Fig. 6A).
Having determined that CTEN inversely regulates
EGFR expression, we next evaluated whether EGFR
expression affects paclitaxel sensitivity. Knockdown of
EGFR expression by transfection of EGFR siRNA into
PC-3-TxR cells restored paclitaxel sensitivity (Fig. 6B).
Next, we investigated the effects of CTEN knockdown
in PC-3 and CTEN overexpression in PC-3-TxR on
sensitivity to the EGFR inhibitor PD153035. There were
no differences in sensitivity to PD153035 regardless of
the increase or decrease of CTEN expression and EGFR
expression in these cells. These data suggested that
PD153035 has the same effect on these cells as long as
EGFR is expressed (Fig. 6C). We also examined
whether PD153035 affected paclitaxel sensitivity in
PC-3-TxR cells. Administration of 1 mM PD153035,
which did not affect proliferation of PC-3-TxR cells
(Fig. 6C), diminished paclitaxel resistance in PC-3-TxR
cells (Fig. 6D). These results indicated that over-
expression of EGFR induced by down-regulation
of CTEN mediates paclitaxel resistance in PC-3-TxR
cells.
CTENProtein ExpressionCorrelatesWithGleason
Score andMetastasis in Prostate Cancer
To examine whether the CTEN protein is differ-
entially expressed in PCa tissues compared to benign
tissues, immunohistochemical staining was performed
on TMA specimens comprised from 89 cores from
44 cases containing normal tissue. All specimens were
graded using the Gleason score. CTEN was differ-
entially expressed in PCa specimens and non-neo-
plastic tissues (Fig. 7 and Table I). In non-neoplastic
tissues, 15 of 16 (94%) expressed high CTEN, 25 of 28
(89%) Gleason score 6 or 7 PCa tissue samples showed
high CTEN expression level, 6 of 12 (50%) Gleason
score 8 PCa tissues showed intermediate expression of
CTEN, and 26 of 32 (81%) Gleason score 9 or 10, PCa
tissues showed low or no expression of CTEN. Positive
staining for CTEN was located mostly in epithelial
cells, but was also noted in some extracellular areas
surrounding neoplastic glands and epithelial cells.
This study showed that CTEN protein expression
was inversely correlated with pathological Gleason
scores of PCa (P< 0.001); CTEN protein was down-
regulated in poorly differentiated PCa tissue.
DISCUSSION
Although hormone-refractory PCa initially respond
to taxanes, eventually the PCa develops resistance to
the taxanes and progresses to end stage disease.
Therefore, it is extremely important to understand the
mechanisms by which PCa becomes resistant to
taxanes to overcome the development of taxane
resistance. The strategy to determine the mechanisms
that contribute to taxane resistance is to identify genetic
or epigenetic aberrations underlying sensitivity/resist-
ance. One mechanism of paclitaxel resistance is over-
expression of P-glycoprotein, the effect of which is
mediated by pumping taxanes out of the cell [9].
However, this mechanism is not always applicable to
all cells. Although PC-3-TxR cells have increased levels
of P-glycoprotein expression, knockdown of P-glyco-
protein had no impact on paclitaxel resistance indicat-
ing that P-glycoprotein does not mediate paclitaxel
resistance in PC-3-TxR cells [13]. Therefore, we
explored other mechanisms of paclitaxel resistance
and showed that down-regulation of CTEN/tensin 4
induces paclitaxel resistance in PC-3-TxR cells. More-
over, overexpression of CTEN not only in PC-3-TxR
cells but also in DU145-TxR cells, in which over-
expression of P-glycoprotein was the main reason for
paclitaxel resistance [13], restored paclitaxel sensitiv-
ity. Furthermore, overexpression of CTEN partly
restored sensitivity to other drugs (DTX, CDDP, VP-16,
EMP, DOX, and VBL). Previously, we confirmed cross-
resistance of PC-3-TxR cells for these drugs except
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CDDP and VP-16 [13]. At that time, we could not clarify
the mechanism through which PC-3-TxR became
resistant to these drugs. The results of the present
study suggested that the reduced expression of CTEN
may be a common mechanism of drug resistance
and that CTEN overexpression by some strategies,
such as gene therapy, may improve chemosensitivity
regardless of CTEN expression in cancer cells.
CTEN is a recently identified focal adhesion mole-
cule that is specifically expressed in the prostate [14].
CTEN belongs to the four-member tensin family,
the proteins belonging to which are localized to
the cytoplasm of focal adhesions [14]. Tensin 1, the
prototype of the family, interacts with actin filaments in
multiple ways [21], and contains an SH2 domain that
binds to phosphotyrosine-containing proteins [22,23].
C-terminal tensin-like (CTEN) is a distant member of
the family with a smaller molecular mass than the
others. CTEN shows homology to other tensin family
members through the presence of the SH2 and PTB
The Prostate
Fig. 6. Effects ofCTENonEGFRexpression andinvolvementof EGFR forpaclitaxelresistance.A:Westernblotting analysis of EGFR.Total
proteins fromPC-3,PC-3-TxR,PC-3-TxR/Neo, andPC-3-TxR/CTENwere subjected toWesternblotting analysis.Totalproteins fromPC-3/
NTsiRNA,andPC-3/CTENsiRNAwerealsosubjectedtoWesternblottinganalysis.Anti-CTEN,anti-EGFR,andanti-GAPDHantibodieswere
employed fordetectionofCTEN,EGFR, andGAPDH,respectively.B: Effects ofEGFRsiRNAonpaclitaxel sensitivity.Twenty-fourhours after
transfectionofPC-3-TxRcellswith 20nMNTsiRNAorEGFRsiRNA, the cellswere treatedwithpaclitaxel for 24hr.Then, the cellswere cul-
turedfor48hrinnormalmedium.C:EffectsofEGFRinhibitorPD153035oncellviabilityofPC-3/NTsiRNAandPC-3/CTENsiRNA.Twenty-four
hours after transfection of PC-3 cells with 20nMNTsiRNA or CTEN siRNA, the cells were treated with the indicated concentration of
PD153035 for 48hr and the numbers of cells were counted.D: Effects of EGFR inhibitor PD153035 on paclitaxel sensitivity. PC-3-TxR cells
were treatedwithpaclitaxelwithorwithout1mMPD153035 for48hr andthenumbersofcellswerecounted.
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domains but it does not have the actin-binding domain
found in other tensin family members [14]. The
function of CTEN in the cytoskeleton, if any, remains
unknown.
In the present study, we showed that modulation of
CTEN expression inversely affects paclitaxel resist-
ance. Due to the role of tensins in the cytoskeleton,
we examined whether alteration of CTEN expression
had an impact on cytoskeletal proteins. Although
CTEN does not have an actin-binding domain, down-
regulation of CTEN in PC-3-TxR cells induced F-actin
expression. The cytoskeleton is crucial for many
cellular processes. For example, the function of
cytoskeletal F-actin is linked to the invasive and
metastatic phenotypes of malignant cancer cells
[24,25]. The cytoskeleton is composed of intermediate
filaments, microfilaments, microtubules, the micro-
trabecular lattice, and other structures characterized
by a polymeric filamentous nature and long-range
order within the cell. The various elements of the
cytoskeleton not only serve in the maintenance of
cellular shape but also have roles in other cellular
functions, including cellular movement, cell division,
endocytosis, apoptosis, and movement of organelles
[26–29]. Cytoskeletal proteins provide the structural
foundation that allows cells to exist in a highly
organized state [30]. These reports suggest that
elevation of F-actin by CTEN down-regulation may
modify the cytoskeletal cell structure to confer resist-
ance to paclitaxel.
Similar to F-actin, we also confirmed that paclitaxel
resistance caused by CTEN down-regulation was
partially mediated through elevation of EGFR expres-
sion. Moreover, EGFR tyrosine kinase inhibitor
restored paclitaxel sensitivity in PC-3-TxR cells. Kita-
zaki et al. [31] showed that an EGFR tyrosine kinase
inhibitor directly inhibited the function of P-glycopro-
tein in multidrug-resistant cancer cells. However, there
seems to be little interaction between P-glycoprotein
and EGFR in PC-3-TxR cells as paclitaxel resistance of
PC-3-TxR cells was not involved in P-glycoprotein in
our previous study [13]. Recently, Pu et al. [32] showed
that the EGFR inhibitor PD168393 potentiated the
cytotoxic effects of paclitaxel synergistically with Bad,
p53, and p21Waf1/Cip1 induction and ERK1/2 inactiva-
tion. Coley et al. [18] demonstrated that ERK-phos-
phorylation and survivin were involved in EGFR
activation in drug-resistant cells. These data suggest
that combination therapy with taxanes and EGFR
tyrosine kinase inhibitors will provide new strategies
to overcome paclitaxel resistance. Our findings suggest
that CTEN may be an upstream target to inhibit EGFR
activity and thus may be worthy of further exploration
for inhibition of drug resistance.
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Total number(–) (þ) (þþ) (þþþ)
Normal 0 1 2 13 16
Gleason score
6, 7 0 3 11 14 28
8 2 4 5 1 12
9, 10 11 15 4 2 32
Total number 13 23 22 30 88
Fig. 7. Immunohistochemistry of CTEN in prostate tissue.
Representative examples of photomicrographs (40 and 200
magnification) showing CTEN expression in the normal prostate
andprostatecancerontissuemicroarrayanalysis.A:CTENexpres-
sioninnormalprostate tissue(intensityþþþ).B:CTENexpression
in prostate cancer with Gleason score 7 (intensityþþ).C: CTEN
expression in prostate cancer with Gleason score 8 (intensity þ).
D: CTEN expression in prostate cancer with Gleason score 9
(intensity).
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Paclitaxel down-regulated CTEN expression
within 48 hr. Little is known about how CTEN
expression is regulated by paclitaxel. Liao et al. [33]
demonstrated that b-catenin up-regulated CTEN
expression in colon cancer. However, we found no
differences in b-catenin expression among PC-3, PC3-
TxR, DU145, and DU145-TxR cells. We are currently
investigating the mechanism of regulation of CTEN
by paclitaxel.
Although we did not observe a difference in cell
proliferation between PC-3-TxR/Neo and PC-3-TxR/
CTEN in vitro, CTEN expression was inversely
associated with PCa Gleason score. Our findings were
in agreement with those of a previous report that CTEN
expression was lower in PCa than in the normal
prostate [14]. In contrast, CTEN mRNA expression
was correlated with tumor progression in lung and
colon cancer [33,34]. This discrepancy could be due to
the differences in tissue type. In addition, the CTEN
gene localizes to chromosome 17q21, a region fre-
quently deleted in PCa [35,36]. Furthermore, due to
tissue differences, the function of CTEN as a focal
adhesion molecule may be different among different
cancer tissues. Regardless, our results suggest that the
expression level of CTEN could be a biomarker of PCa
progression. In addition, the observation that only 60%
of men with androgen non-responsive PCa respond to
initial taxane therapy indicates that a large number of
PCa patients are initially resistant to taxanes. If we
could predict the responsiveness to taxanes prior
to chemotherapy, we could avoid administration of
unnecessary and toxic taxane-based treatment regi-
mens. Our results suggest that evaluation of CTEN
expression in PCa tissues may be a useful way to
predict taxane responsiveness. Unfortunately, it is
extremely difficult to obtain recurrent samples from
patients before chemotherapy because the recurrence is
often in bone metastatic lesions and not in the prostate.
We are now collecting data from HRPC patients treated
with taxanes and will investigate the correlation
between CTEN expression at diagnosis and duration
of taxanes responsiveness.
In conclusion, we showed that down-regulation
of CTEN causes paclitaxel resistance in PCa cells.
This was associated with elevation of F-actin and
increased EGFR, which contributed to this resistance.
Moreover, expression of CTEN was inversely corre-
lated with Gleason Score, indicating that poorly
differentiated PCa may have increased resistance
to taxane-based therapy. Accordingly, defining the
function and regulation of CTEN may lead to
new chemotherapy strategies for those patients
initially resistant or that later develop resistance to
taxanes.
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